Theriva Reports $1.5 Million Third-Quarter Loss as VIRAGE2 Enrollment Advances
Theriva Biologics (TOVX) reported a net loss attributable to common stockholders of $1.5 million, or $0.03 per basic and diluted share, for the third quarter ended September 30, 2026. The company reported cash and cash equivalents of $8.5 million at quarter-end and said its cash runway extends into the first quarter of 2027.
Theriva said VIRAGE2 enrollment is expected to be completed in the fourth quarter of 2026, with initial pharmacodynamic and safety data anticipated by the third quarter of 2027. The company also completed the October sale of its SYN-004 antibiotic-degrading enzyme portfolio to Biossil Labs.
- Third-quarter general and administrative expenses were $923,000, down 51% year over year.
- Research and development expenses were $612,000, down 76% year over year.
- Biossil paid $350,000 upfront for the SYN-004 portfolio; potential payments include up to $3 million in regulatory milestones and up to $88 million in sales milestones, plus royalties.
- License revenue was zero for the third quarter; nine-month license revenue was $300,000.
$TOVX Hedge Fund Activity
We have seen 10 institutional investors add shares of $TOVX stock to their portfolio, and 7 decrease their positions in their most recent quarter.
Here are some of the largest recent moves:
- VIRTU FINANCIAL LLC removed 166,080 shares (-65.6%) from their portfolio in Q2 2026, for an estimated $41,553
- JANE STREET GROUP, LLC added 154,888 shares (+87.5%) to their portfolio in Q2 2026, for an estimated $38,752
- TWO SIGMA SECURITIES, LLC removed 85,493 shares (-81.2%) from their portfolio in Q2 2026, for an estimated $21,390
- NORTHERN TRUST CORP added 82,700 shares (+inf%) to their portfolio in Q2 2026, for an estimated $20,691
- RENAISSANCE TECHNOLOGIES LLC added 63,710 shares (+inf%) to their portfolio in Q2 2026, for an estimated $15,940
- UBS GROUP AG removed 47,070 shares (-77.1%) from their portfolio in Q3 2026, for an estimated $10,590
- XTX TOPCO LTD removed 40,752 shares (-43.1%) from their portfolio in Q2 2026, for an estimated $10,196
To track hedge funds' stock portfolios, check out Quiver Quantitative's institutional holdings dashboard. You can access data on hedge funds moves and 13F filings through the Quiver Quantitative API 13F endpoint.